AYTU BIOPHARMA, INCAYTUEarnings & Financial Report
Aytu BioPharma, Inc. is a US-based specialty pharmaceutical company that develops and commercializes a portfolio of consumer healthcare products and prescription therapeutics. Its key offerings cover cold and allergy treatments, sexual health solutions, and therapies for rare pediatric conditions, serving patients and healthcare providers across the United States.
AYTU Q2 FY2026 Key Financial Metrics
Revenue
$15.2M
Gross Profit
$9.6M
Operating Profit
$-2.0M
Net Profit
$-10.6M
Gross Margin
63.5%
Operating Margin
-13.0%
Net Margin
-69.8%
YoY Growth
-6.5%
EPS
$-1.05
AYTU BIOPHARMA, INC Q2 FY2026 Financial Summary
AYTU BIOPHARMA, INC reported revenue of $15.2M (down 6.5% YoY) for Q2 FY2026, with a net profit of $-10.6M (down 1443.1% YoY) (-69.8% margin). Cost of goods sold was $5.5M, operating expenses totaled $11.6M.
Key Financial Metrics
| Total Revenue | $15.2M |
|---|---|
| Net Profit | $-10.6M |
| Gross Margin | 63.5% |
| Operating Margin | -13.0% |
| Report Period | Q2 FY2026 |
AYTU BIOPHARMA, INC Annual Revenue by Year
AYTU BIOPHARMA, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $66.4M).
AYTU BIOPHARMA, INC Quarterly Revenue & Net Profit History
AYTU BIOPHARMA, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $15.2M | -6.5% | $-10.6M | -69.8% |
| Q1 FY2026 | $13.9M | -16.2% | $2.0M | 14.1% |
| Q4 FY2025 | $15.1M | +3.7% | $-19.8M | -130.9% |
| Q3 FY2025 | $18.5M | +31.6% | $4.0M | 21.6% |
| Q2 FY2025 | $16.2M | -13.5% | $788.0K | 4.9% |
| Q1 FY2025 | $16.6M | -7.0% | $1.5M | 8.9% |
| Q4 FY2024 | $14.6M | -52.5% | $-4.6M | -31.6% |
| Q3 FY2024 | $14.0M | -38.3% | $-2.9M | -20.6% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.0M | $14.6M | $16.6M | $16.2M | $18.5M | $15.1M | $13.9M | $15.2M |
| YoY Growth | -38.3% | -52.5% | -7.0% | -13.5% | 31.6% | 3.7% | -16.2% | -6.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $128.9M | $118.1M | $115.8M | $116.2M | $124.2M | $124.2M | $125.0M | $122.0M |
| Liabilities | $98.1M | $90.4M | $86.0M | $85.5M | $89.3M | $105.2M | N/A | N/A |
| Equity | $30.8M | $27.7M | $29.8M | $30.8M | $34.9M | $19.0M | $23.2M | $14.2M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-254000 | $-788000 | $-1.2M | $2.9M | $-6.5M | $2.8M | $-618000 | $3.7M |